Showing 4291-4300 of 5957 results for "".
- Horus Pharma Group Launches Nordic Subsidiaryhttps://modernod.com/news/horus-pharma-group-launches-nordic-subsidiary/2481515/Horus Pharma, an independent French laboratory specializing in ophthalmology, has opened of a new subsidiary. From its base in Stockholm, Sweden, Horus Pharma Nordic will cover Sweden, Norway, Finland and Denmark. Horus Pharma develops, patents and markets preservative-free ey
- Celanese Enters Agreement with Glaukos for Sustained Release Glaucoma Treatmenthttps://modernod.com/news/celanese-enters-agreement-with-glaukos-corporation-for-sustained-release-glaucoma-treatment/2481514/Celanese announced that it has entered into an agreement with Glaukos Corporation to supply its VitalDose Drug Delivery Platform for use as a component in Glaukos’ iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with primary open-ang
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d
- First Myopia Action Month Announced for Septemberhttps://modernod.com/news/first-myopia-action-month-announced-for-september/2481510/Myopia Profile announced its launch of Myopia Action Month to channel myopia awareness into action. Taking place in September, the inaugural event is designed to bring 4 weeks of global education, industry collaboration, and encouragement to ECPs to empower them to take effect
- TearRestore’s Thermal Mask & HylaWipe Tea Tree Eyelid Wipes Now Available at Targethttps://modernod.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at Target stores nationwide and at Target.com. The Thermal Mask and Eye Wipe offer alternative options to artificial tears and are designed to directly address the
- Abionyx Pharma Announces Its Strategy in Ophthalmologyhttps://modernod.com/news/abionyx-pharma-announces-its-strategy-in-ophthalmology/2481506/France-based Abionyx Pharma announced announced its strategy in ophthalmology and new positive preclinical results in two technological platforms: apotherapy and biovectorisation. "The acquisition of IRIS Pharma, one of the world leaders in contract research in ophthalmology,
- Kala Pharmaceuticals Appoints Francis Mah, MD, as Chief Medical Advisorhttps://modernod.com/news/kala-pharmaceuticals-appoints-francis-mah-md-as-chief-medical-advisor/2481501/Kala Pharmaceuticals announced the appointment of Francis Mah, MD, as Chief Medical Advisor. In this new role, Dr. Mah will provide support for Kala’s clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in
- Andreas C. Kühnel Appointed as Geschäftsführer Managing Director at VSY Biotechnologyhttps://modernod.com/news/andreas-c-kuhnel-appointed-as-geschaftsfuhrer-managing-director-at-vsy-biotechnology/2481500/VSY Biotechnology has announced the appointment of Andreas Christoph Kühnel as its new Managing Director. In this new role, Mr. Kühnel will be responsible for developing and expanding VSY Biotechnology’s operations on a global scale. Mr. Kühnel brings expertise and
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for RP and LCA Gene Therapyhttps://modernod.com/news/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-12-clinical-trial-for-rp-and-lca-gene-therapy/2481499/Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 phase 1/2 trial. OCU400 is a gene therapy candidate for retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). “This approval moves us one step closer in our efforts to bri
- Study: Reduced Oxygen Transport to the Retina Contributing to Damage to the Fine Blood Vessels Causes Diabetic Retinopathyhttps://modernod.com/news/study-reduced-oxygen-transport-to-the-retina-owing-to-damage-to-the-fine-blood-vessels-causes-diabetic-retinopathy/2481492/Researchers in Austria have now found evidence for a previously suspected connection: reduced oxygen transport to the retina contributes to damage to the fine blood vessels, causing diabetic retinopathy. A common complication of diabetes, this retinal damage can ultimately lead to blind